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Abstract
Background: Systems chemical biology and chemogenomics are considered critical, integrative disciplines in
modern biomedical research, but require data mining of large, integrated, heterogeneous datasets from chemistry
and biology. We previously developed an RDF-based resource called Chem2Bio2RDF that enabled querying of such
data using the SPARQL query language. Whilst this work has proved useful in its own right as one of the first
major resources in these disciplines, its utility could be greatly improved by the application of an ontology for
annotation of the nodes and edges in the RDF graph, enabling a much richer range of semantic queries to be
issued.
Results: We developed a generalized chemogenomics and systems chemical biology OWL ontology called
Chem2Bio2OWL that describes the semantics of chemical compounds, drugs, protein targets, pathways, genes,
diseases and side-effects, and the relationships between them. The ontology also includes data provenance. We
used it to annotate our Chem2Bio2RDF dataset, making it a rich semantic resource. Through a series of scientific
case studies we demonstrate how this (i) simplifies the process of building SPARQL queries, (ii) enables useful new
kinds of queries on the data and (iii) makes possible intelligent reasoning and semantic graph mining in
chemogenomics and systems chemical biology.
Availability: Chem2Bio2OWL is available at http://chem2bio2rdf.org/owl. The document is available at http://
chem2bio2owl.wikispaces.com.
Background
Recent efforts [1-3] in the Semantic web have involved
conversion of various chemical and biological data
sources into semantic formats (e.g., RDF, OWL) and
linked them into very large networks. The number of
bubbles in Linked Open Data (LOD) [4] has expanded
rapidly from 12 in 2007 to 203 in 2010. This richly
linked data allows answering of complex scientific ques-
tions using the SPARQL query language [5], finding
paths among objects [6], and ranking associations of dif-
ferent entities [7,8]. Our previous work on Chem2-
Bio2RDF [3] offers a framework to data mine systems
chemical biology and chemogenomics data, as exempli-
fied by the examples given in our paper: compound
selection in polypharmacology, multiple pathway inhibi-
tor identification and adverse drug reaction - pathway
mapping. However, without an ontology and associated
annotation, the utility of the resource is semantically
very limited - for example results cannot be refined
based on criteria of the type of relationship between
entities (e.g., activation or inhibition between compound
and protein). Even when it is possible to create a
SPARQL query, the lack of ontology increases the com-
plexity of the query: for example, when searching for
t h et a r g e t so fag i v e nd r u g ,w eh a v et os p e c i f yi nt h e
SPARQL exactly which databases are to be searched and
how to combine the results. SPARQL construction thus
requires understanding of the RDF schema of each data
source, greatly increasing its complexity. The owl:
sameAs (or seeAlso) predicate is used as the primary
method for linking multiple data sources sharing com-
mon information. Such database level integration does
not satisfy our requirement that a query is constructible
in a natural and intuitive manner.
An ontology is a formal description of knowledge as a
set of concepts within a domain, and the relationships
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(OWL) is a language for making these descriptions
designed for use within Semantic Web. A variety of
ontologies in the life sciences have been developed.
Gene Ontology (GO) [9] is arguably the most widely
used ontology in life sciences. It aims to formalize the
representation of information about biological processes,
molecular functions, and cellular components across
multiple organisms. As a part of GO project, the
Sequence Ontology consists of a set of terms and rela-
tionships used to describe the features and attributes of
biological sequence [10]. PRotein Ontology (PRO)
describes the relationships of proteins and protein evo-
lutionary families and represents the multiple protein
forms of a gene locus [11]. Structurally similar to GO,
ChEBI provides ontologies of chemical compounds of
biological interest based on their chemical structural
and functional features [12]. Disease Ontology (DO)
[13] is an open source ontology for the integration of
human disease data. Terms in DO are well defined,
using standard references and linked to well-established,
well-adopted terminologies used in other disease presen-
tations such as MeSH, OMIM, and UMLS. Other
domain-specific ontologies have also been developed,
including pharmacogenomics [14], ligand protein inter-
action [15,16], Disease-Drug Correlation Ontology
(DDCO) [17], biological pathways (BioPAX) [18], Trans-
lational Medicine Ontology [19] and neuromedicine
(SWAN) [20]. Particularly, several ontologies have been
developed recently to formalize chemical biology experi-
ments and provide guidance for data annotation. For
example, the Minimum Information About a Bioactive
Entity (MIABE) [21] aims to provide guidelines for
reporting bioactive entities explicitly. BioAssay Ontology
[22] is developed to standardize the description of HTS
experiments and screening results. DDI [23] and OBI
[24] present integrative and semantic frameworks in
drug discovery investigation and biomedical investiga-
tions respectively. A number of upper ontologies such
as Basic Formal Ontology (BFO) [25] are developed to
support domain ontology building as well. Many of the
ontologies are deposited in the OBO foundry [26] or
NCBO BioPortal [27], for public access. Using ontolo-
gies to integrate data and reason has been widely prac-
ticed in life sciences. Baitaluk and Ponomarenko built
IntegromeDB to semantically integrate over 100 experi-
mental and computational data sources relating to geno-
mics, transcriptomics, genetics, and functional and
interaction data concerning gene transcriptional regula-
tion in eukaryotes and prokaryotes [28]. Holford et al.
created logical rules using Semantic Web Rule Language
to answer research questions pertaining to pseudogenes
[29].
Systems Chemical Biology [30] (and its sub-discipline
of chemogenomics) is a new discipline studying how
chemicals interact with the whole biological systems, the
data of which cover a wide range of entities (com-
p o u n d s ,d r u g s ,p r o t e i n s ,g e n e s ,d i s e a s e s ,s i d e - e f f e c t s ,
pathways, and so on) and various relations between enti-
ties such as drug-drug interaction, drug-target interac-
tion, protein-protein interaction and so on. Within this
field, chemogenomics is specifically concerned with
ways of modeling the relationships between chemical
compounds, genes and protein targets. Until now, no
systematic ontologies have been developed for chemoge-
nomics, or for the parent field of Systems Chemical
Biology. In this work, we describe the creation of such
an ontology that covers chemogenomics and the entities
of Systems Chemical Biology described above, as defined
by the scope of our Chem2Bio2RDF data resource and
demonstrate its usage as a knowledge base for study.
Methods
The process we used to develop Chem2Bio2OWL is
s h o w ni nF i g u r e1 .I np a r t i c u l a r ,o u ro n t o l o g yw a s
driven by use-case queries that can be found on the
Chem2Bio2OWL website, which are difficult or impossi-
ble to answer without an ontology. Some examples
(semantic terms highlighted in boldface) are:
1. What are the protein targets of the drug
Troglitazone?
2. Find PPARG inhibitors with molecular weight
less than 500.
3. Which pathways will be affected by Troglitazone?
4. Find all bioassays that contain activity data for a
particular target.
5. What liver-expressed proteins can a given com-
pound interact with?
6. Which proteins a r ea b l et ointeract with protein
PPARG in vivo?
7. Which drugs are used to treat diabetes but with-
drawn from market?
8. Which assays test the activity of Troglitazone
against PPARG ? preferably give the literature.
Classes, relations and data properties
Once we created an initial set of terms derived from
use-case queries, we defined a set of primary classes:
SmallMolecule, Drug, Protein Target, Disease, SideEf-
fect, Pathway, BioAssay, Literature and Interaction
(Table 1) based partially on the BioPAX classes [18].
BioPAX offers a standard, well defined representation of
biological pathway data using OWL and it has been
widely used in biological data integration [15,31]. We
imported the terms from BioPAX and made subsequent
extensions based upon our use cases. The primary
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data structure. SmallMolecule, Drug and Protein were
put under PhysicalEntity. Their relation with Disease and
SideEffect were elaborated under Interaction, which is
further classified into DrugInducedSideEffect, DrugTreat-
ment, DrugDrugInteraction, ProteinProteinInteraction
and ChemicalProteinInteraction. BioAssay and Literature
serve as Evidence to support the relations. Pathway was
treated as a ‘black box’ since its instance data is just path-
way name. Other than Interaction, we did not intend to
further classify other individual major classes.
After major classes were determined, some utility
classes were created to help present primary classes, of
which a single class is insufficient to present the hier-
archical behavior. For instance, ChemicalStructure con-
sisting of structure format and structure representation
is considered as a utility class to present the structure of
a small molecule. A small molecule may have multiple
structure representations, thus there are several
instances of ChemicalStructure relating to the small
molecule. Without the bearer small molecule, the
instance of ChemicalStructure is meaningless.
Collectscientific
questions
Proposeframework
and basic classes
RDFdataset,Database
schema
andbasicclasses
Defineclasses,relations Externalontologies&
anddataproperties
Integrate domain
controlledvocabulary
External Individual Integratedomain
ontolgies
ExternalIndividual
domainontologies
Evaluateontology
Populateontology Chem2Bio2RDFdataset
Reasoningandgraph
mining
Figure 1 Workflow for the development of Chem2Bio2OWL.
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properties (or contexts) such as experimental conditions
and references were separated out as individual classes,
and were placed under Interaction; otherwise, they were
presented as object properties. Relational Ontology (RO)
[33] was imported to help present basic relations. For
example, ProteinProteinInteraction not only covers the
binary relation between two proteins, but also affiliates its
experimental conditions (e.g., organism and interaction
type). Protein serves as a participant in that interaction.
Similarly, Chemical and Protein serve as participants in
the ChemicalProteinInteraction, which includes other
information such as the strength of interaction. Figure 2
shows major classes and their relations.
Data properties appeared in the original database
sources were not fully covered, instead, only the impor-
tant ones related to our purpose (chemogenomics and
systems chemical biology). This simplifies the ontology
without losing essential knowledge. The terms including
data property name, class name and relation name were
manually mapped to terms in relevant ontologies in the
OBO and NCBO BioPortal, and the terms in the exist-
ing ontologies are preferred if multiple terms happened.
For example, for a chemical formula we chose chemical-
Formula as this term is used in BioPAX. In addition, the
term must conform to our name convention. If there
were multiple results or no results at all, we would use
the terms from primary data bases. A table was created
to map data source terms to the standardized and later
was applied to annotate instances. The properties of
class, object and data property were further edited in
protégé [34].
Chemogenomic interactions
Classification of chemogenomic interactions (compound-
protein or drug-target) is extremely important and yet
complicated [35]. We consider the interaction from two
aspects: 1) how chemicals do with proteins (called Che-
micalRegulatesProtein) 2) how proteins do with chemicals
(called ProteinRegulatesChemical). ChemicalRegulatesPro-
tein further includes regulation of protein activity, expres-
sion of protein, post-modification of protein and so on.
ProteinRegulatesChemical includes catalysis of chemical,
transportation of chemical and so on. Interaction types
described in the Comparative Toxicogenomics Dataset
(CTD) [36] were used as a basis for relational terms,
being further developed by the addition of new interac-
tion terms such as activation and inhibition. The terms
were mapped to GO if exist. In total, 61 interaction
classes were created. The experiment to examine the
interaction was presented in BioAssay class. The BioAs-
say outcome includes measurement (e.g., EC50, IC50, Ki,
Table 1 Primary classes, their description, sample instance data sources and the number of sample annotated
instances.
primary classes description sample instance data sources # of sample
instances
SmallMolecule a small bioactive molecule PubChem, ChEBI 15509
Drug a chemical used in the treatment, cure, prevention, or
diagnosis of disease
DrugBank, PharmGKB, TTD 6544
Protein a physical entity consisting of a sequence of amino
acids
Uniprot, HGNC, GOA 12242
BioAssay an experiment to measure the effects of some
substance on target, cell or a living organism
PubChem BioAssay, ChEMBL, BindingDB, PDSP 26861
Disease any condition that causes pain, dysfunction, distress or
social problems
OMIM, DO 8724
SideEffect undesired effect from a medicine SIDER 1385
Literature a scientific article Medline 28392
Pathway a set or series of a biological interactions KEGG, Reactome 347
Interaction
DrugDrug-
Interaction
a drug affects the activity of another drug DrugBank, DCDB 9690
ProtienProtien-
Interaction
two or more proteins bind together HPRD, DIP, BioGrid 54345
DrugInduced-
SideEffect
a drug interaction that results in side effect SIDER 61102
DrugTreatment the use of drug to treat disease Diseasome 812
ChemicalProtein-
Interaction
genomic response to chemical compounds ChEMBL, BindingDB, PDSP Ki, TTD, BindingMOAD,
DrugBank, CTD, MATADOR, Array-Express, KEGG
47282
Data sources were described in [32]
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Figure 3 shows how these terms are used in a small net-
work containing drug Troglitazone, gene PPAR-Gamma
(PPARG), their interaction and the associated experiment.
Only one entry in Chem2Bio2RDF is presented in this
figure, there are 43 entries recording this interaction in 6
chemogenomics databases (available at http://cheminfov.
informatics.indiana.edu/rest/Chem2Bio2RDF/cid_gene/
5591:PPARG).
Implementation
Figure 4 shows the data integration workflow we used to
populate the ontology. Customized Java scripts along
with the OWL API Java package [37] were used to auto-
mate the annotation of Chem2Bio2RDF data using
Chem2Bio2OWL. Pellet reasoning [38] was then applied
to reason new relations. The annotated data plus new
relations were uploaded to the Virtuoso triple store [39]
for querying. Efforts were made to cope with data redun-
dancy, inconsistence and provenance. Data redundancy is
originated from the homogeneity of data source of the
objects. Chemical compounds for example were pre-
sented as various formats (e.g., SMILES, InChi, MOL,
etc.) and many data sources have their own identifiers to
present compounds. The URI of individual instance in
Chem2Bio2OWL is based on the primary data source ID
or fake ID if primary ID is unavailable. PubChem as the
largest public compound hub is considered as the pri-
mary source for chemicals. Its identifier Compound ID
(CID) was used to identify compounds (e.g., http://
chem2bio2rdf.org/chem2bio2owl#compound5591). The
compounds with unknown CIDs were assigned CIDs by
searching PubChem using InChi, a universal structure
representation. A fake CID was assigned if the compound
did not exist in PubChem. Drug, protein and side effect
are using DrugBank ID, UNIPROT entry name, and
UMLS ID as primary IDs. Pathway name is used as path-
way identifier. Diseases can be presented as MESH,
OMIM ID, UMLS or free text, but no universal disease
identifier has been agreed to present them. Since the Dis-
ease Ontology [13] has already mapped terms to various
public disease identifiers, we adopted Disease Ontology
Interaction
SideEffect
participates inÆ
is_a
Disease DrugInducedSideEffect
participates_inÆ
Åhas_participant
participates_inÆ
Åhas_participant
participates_inÆ
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ti i t i Æ
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Methylation
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Figure 2 Overview of Chem2Bio2OWL. Only part of classes (presented as nodes) and their relations (presented as edges) are visualized. Some
classes in ChemicalProteinInteraction are ignored due to the limited space.
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Page 5 of 11ID as primary ID. The free texts occurred in TTD, Disea-
some and other sources were mapped to disease ontology
using string matching algorithms.
Maintaining data provenance (i.e. its source and his-
tory) is useful for data validation, confidence weighting
and to facilitate data update and maintenance. The class
UnificationXref defines a reference to an entity in an
external resource that has the same biological identity as
the referring entity. Its data properties DB and ID pre-
sent the name of external source and the related identi-
fier respectively; comments is used to put additional
information such as why, who, how and how if needed.
For example, compound5591 has ID 5591 in PubChem
and ID 9753 in ChEBI, they are represented using class
UnificationXref. For some assertions (e.g., interaction),
PublicationXref is applied to record the original paper
reporting the assertion.
Table 1 shows the statistics of sample instances of pri-
mary classes as well as sample primary data sources. The
total number of triples is 3,084,836, and it increases to
4,411,817 after reasoning. They were later used for eva-
luation and are available at Chem2Bio2OWL web site.
Results
Other than the cases studied before [3,32], we applied
the annotated data to answer various questions which
are detailed on our website. 20 SPARQLs are available
at our website. Here we discuss a few examples.
Drug related target identification
Identification of potential targets for drugs is important
for discovering new therapeutic applications as well as
identifying potential undesirable side-effects (“off-target
interactions”). These kinds of interactions are described
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has biologicalInterest true
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Figure 3 Ontological representation of Troglitazone, PPARG and their binding association tested in a bioassay experiment.T h er e a l
data are available in Chem2Bio2RDF website.
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Figure 4 Workflow for ontology population.
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sets: PubChem BioAssay, ChEMBL and BindingDB con-
tain binding experiments; PharmGKB contains genetic
variations upon drug response; CTD and Array Express
contain expression data; KEGG contains interactions in
pathways. To answer the question: “What are the possible
targets of drug (e.g., Troglitazone)? “ previously required a
complex SPARQL query explicitly referencing each data
set individually [32]. The following SPARQL presents the
searching of two chemogenomics database:
PREFIX compound: <http://chem2bio2rdf.org/pub-
chem/resource/>
PREFIX bindingdb: <http://chem2bio2rdf.org/bin-
dingdb/resource/>
PREFIX drugbank: <http://chem2bio2rdf.org/drug-
bank/resource/>
PREFIX uniprot: <http://chem2bio2rdf.org/uniprot/
resource/>
SELECT ?uniprot_id
FROM <http://chem2bio2rdf.org/pubchem>
FROM <http://chem2bio2rdf.org/drugbank>
FROM <http://chem2bio2rdf.org/bindingdb>
FROM <http://chem2bio2rdf.org/uniprot>
WHERE {
{?compound compound:CID ?compound_cid. FIL-
TER (?compound_cid = 5591). #Troglitazone Pub-
Chem CID is 5591
?chemical bindingdb:cid ?compound.
?target bindingdb:Monomerid ?chemical.
?target bindingdb:ic50_value ?ic50. FILTER (?ic50
< 10000).
?target bindingdb:uniprot ?uniprot .
?uniprot uniprot:uniprot ?uniprot_id .
}
UNION
{?compound compound:CID ?compound_cid . FIL-
TER (?compound_cid = 5591) .
?drug drugbank:CID ?compound .
?target drugbank:DBID ?drug .
?target drugbank:SwissProt_ID ?uniprot .
?uniprot uniprot:uniprot ?uniprot_id .
}
}
GROUP BY ?uniprot_id
The query combines the searching of two databases
BindingDB and DrugBank, which have their own RDF
structures. BindingDB and DrugBank use Monomerid
and DBID as compound identifiers separately, and adopt
uniprot and SwissProt_ID as target identifiers. They
have to be distinct in the SPARQL. The SPARQL would
become more complicated if more chemogenomics data-
sets were considered. We can now create a ‘one step’
query that is independent of the data source by virtue of
our ontology:
PREFIX c2b2r: <http://chem2bio2rdf.org/chem2-
bio2rdf.owl#>
PREFIX bp: <http://www.biopax.org/release/biopax-
level3.owl#>
PREFIX ro: <http://www.obofoundry.org/ro/ro.owl#>
PREFIX rdfs: <http://www.w3.org/2000/01/rdf-
schema#>
PREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syn-
tax-ns#>
select distinct ?target_name
from <http://chem2bio2rdf.org/owl#>
where
{
?chemical rdfs:label “Troglitazone"^^xsd:string;
ro:participates_in ?interaction .
?interaction rdf:type c2b2r:
ChemicalProteinInteraction;
ro:has_participant ?target .
?target rdf:type bp:Protein;
rdfs:label ?target_name .
}
The query is interpreted as: chemical with label Tro-
glitazone participates in an interaction which is a chemi-
cal protein interaction, and the interaction has a
participant, which is of type protein.
For Troglitazone, other than its primary target PPARG,
we found the activities of 10 targets are associated with
the drug, and the gene expression of 22 targets are either
up or down regulated under the treatment of Troglita-
zone. For example, Troglitazone could be metabolized by
several cytochrome P450 enzymes (CYP17A1, CYP2C19,
CYP2C8, CYP2C9 and CYP3A4) and also could affect
the activity of ABCB11 (bile salt export pump), which
may account for the liver toxicity problems of Troglita-
zone [40]. To further explore their interactions, another
question might be raised: “What assays test the activity
of Troglitazone against PPARG ?“. After running the
SPARQL below, 9 bioassay experiments appeared in
5 articles were fetched. Although all assays show the
positive activity of Troglitazone against PPARG, their
values are different under different experiments, the detail
of which could be further explored via associated refer-
ences.
{
?interaction bp:evidence ?bioAssay;
?bioAssay rdf:type c2b2r:BioAssay;
c2b2r:description ?bioAssayDescription;
c2b2r:hasOutcome [c2b2r: measurement ?
measurement;
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c2b2r: value ?value;
c2b2r: unit ?unit
].
optional {?bioAssay bp:xref [c2b2r: title ?title]}
}
Following the steps in the previous query, this query is
interpreted as: this interaction has evidence which is a
bioassay; the assay has description and outcome, and
has reference if exists.
Target inhibitor/activator searching
Pregnane × receptor (NR1I2) is a transcriptional regula-
tor of the expression of xenobiotic metabolism and
transporter genes. It has multiple binding sites, account-
ing for different functions. Its agonists at the ligand-
binding domain would trigger up-regulation of genes,
increase the metabolism and excretion of therapeutic
agents, and cause drug-drug interactions, but its antago-
nists counteract such interactions [41]. Due to different
binding sites, the two types of compounds may be quite
different structurally. Using Chem2Bio2OWL, we are
able to answer this question: “Find NR1I2 agonists and
remove compounds with weight ≥ 500“. The following
SPARQL was used to retrieve 37 agonists. Their struc-
tures are quite different with 6 antagonists retrieved
from another query, indicating the significance of classi-
fying the ligands.
{
?interaction rdf:type c2b2r:ReceptorAgonistActivity;
#or ReceptorAntagonistActivity for antagonist search
ro:has_participant ?chemical .
?chemical rdf:type bp:SmallMolecule;
c2b2r:hasPhysicalProperty [c2b2r:molecular-
Weight ?weight];
bp:structure [bp:structureFormat “openeye_-
can_smiles"^^xsd:string; bp:structureData ?
structureData].
FILTER(?weight < 500).
}
This query is interpreted as: this interaction is a recep-
tor agonist activity and has participant which is a small
molecule; the molecule has physical property weight
smaller than 500, as well as structure with openeye_-
can_smiles format.
Thiazolidinedione side effect study
Thiazolinediones are a class of insulin sensitizing drugs
widely used to control diabetes. However, several drugs
in the class have suffered from side effects resulting
in drug withdrawal (Troglitazone) or restriction (Rosigli-
tazone). These drugs have a high degree of chemical
similarity, but very different side-effects. Troglitazone is
associated with an idiosyncratic reaction leading to drug-
induced hepatitis or other liver toxicities [42] while Rosi-
glitazone is associated with an increased risk of myocar-
dial infarction [43]. The systems chemical biology
approach has been shown to have the potential to explain
drug side effects [44]. Figure 2 illustrates two systems
chemical biology approaches to investigate the side effects
of Troglitazone and Rosiglitazone. We hypothesize that
their related targets might somehow link to disease
related genes/proteins, which might explain their side
effects. Identification of drug targets and disease related
genes/proteins are two major steps. Via the SPARQL for
drug related target identification, Troglitazone and Rosi-
glitazone were found to be associated with to 31 and 48
unique targets respectively via different interactions. Two
approaches could be used to find disease related genes/
proteins, but the first step would map disease terms into
Chem2Bio2OWL disease data. We mapped liver toxicity
to hepatobiliary disease in disease ontology which has
subclasses such as hepatitis, cholestasis and hepatorenal
syndrome, that could be further linked to disease genes
in our system (Figure 5). ABCB11 is one of the liver dis-
ease related genes and its activity is affected by Troglita-
zone. ABCB11 involves in the liver bile acid
transportation and metabolism (from GO terms for
ABCB11). It is not surprising that the change of its activ-
ity will result in liver diseases. Similarly, we mapped heart
attack to heart disease in the disease ontology that
includes heart failure, endocarditis, pericarditis, etc, which
are linked to 7 disease genes. However, no overlap
between disease genes and Rosiglitazone related targets
was found; therefore we then turned to find disease
related targets. First, the drugs causing heart disease were
searched and their related targets were further identified,
grouped, and ranked by the number of their common
drugs. The higher ranking indicates the higher possibility
linking to the side effect. The top 10 targets are CYP3A4,
CYP2C9, ABCB1, CYP1A2, PTGS2, CASP3, CYP2D6,
CYP3A5, CYP2C19 and PPARG. The top one CYP3A4
for example is shared by 41 drugs, out of 181 total heart
disease related drugs. Some high ranked targets like
CYP3A4 also are affected by Troglitazone, nevertheless,
the activity of CYP2D6 shared by 24 heart disease related
drugs is affected only by Rosiglitazone, it was not found
in the Troglitazone related targets. Further literature
search indicates that CYP2D6 plays a very important role
in cardiovascular disease [45]. Although further experi-
mental evaluation would be preferred, this scenario does
demonstrate the usage of Chem2Bio2OWL to investigate
systems chemical biology problems.
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Chem2Bio2OWL constructs a complex network with
semantic meaning of every component, in which nodes
are instances and they are linked by certain semantic
relations. This rich set allows the application of various
graph mining techniques to discover interesting patterns
[46], including simple path-finding between entities. Fig-
ure 6 shows how multiple paths link between a benzimi-
dazole analogue (CID:44143441) and the hERG (KCNH2)
target. Although there is no reported direct interaction
between this compound and this target, the graph visuali-
zation suggests their indirect associations. First, three
structurally similar compounds (CID:44143442, 44143438
and 44143439) with very high structural similarity to the
compound, are able to bind to KCNH2. Second, the tar-
get of benzimidazole analogue kappa-type 3 opioid recep-
tor (OPRL1) shares many common compounds with
KCNH2, indicating that the compound active in OPRL1
is also possibly active against KCNH2. Third, shared GO
terms further manifest the similarity of two targets.
Chem2Bio2RDF already is being used in semantic graph
mining [8,47,48] to detect various complex relations
among drug, target and diseases. The new annotated data
greatly increases the utility of this approach.
Discussion and Conclusions
Many current methods and tools often convert data into
RDFs directly from original data bases. They prove use-
ful in their own right to link multiple datasets, but with-
out a formal ontology to model the concepts and their
relations, the linked data would not fully demonstrate
the capability of semantics, limiting its further usage in
data integration and reasoning. In addition, adding evi-
dence and provenance to support assertions is of great
importance to keep track of the record, but it has not
been well implemented in the current RDFization pro-
cess. Chem2Bio2OWL provides a high level structure of
the entities and relations according to use case queries
and instance data structures, and considers evidence
and provenance. However, the case driven ontology
troglitazone rosiglitazone
activity activity binding activity binding
CYP3A4 PPARG ABCB11 CYP2D6 CYP3A4 PPARG
activity binding activity
causeSideEffect causeSideEffect
ABCB11 ACHE KCNH2 CYP2D6 ATP8B1 CYP7B1
Interation Interation
caused by donepezil procainamide dasatinib thalidomide
Interation
Interation
Interation
Interation Interation
causedby causedby
causedby donepezil procainamide dasatinib thalidomide
causedby causedby
causedby
causedby
causedby
causedby
cholestasis heartfailure endocarditis
isa
pericarditis hepatitis
is a
isa
hepatorenal
syndrome
isa is a is a
hepatobiliary disease heartdisease
isa isa isa
Figure 5 Thiazolidinediones side effect study: left figure shows the association between Troglitazone and liver toxicity; right figure
shows the association between Rosiglitazone and heart disease.
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to many ‘top down’ approaches which aims to model
domain knowledge oriented from philosophical perspec-
tive, nevertheless, our work serves as a local engineering
solution to address the urgent needs in this area. The
integrative searching of systems chemical biology data
can be performed in a very intuitive and efficient way.
Other than Chem2Bio2RDF, some public datasets (e.g.,
Bio2RDF and LODD) could be annotated using
Chem2Bio2OWL.
Further efforts should be made to align Chem2-
Bio2OWL with basic ontology (i.e., BFO and RO) and
other Bio-ontologies. For example, the major classes
PhysicalEntity and Disease are continuant under BFO,
and Pathway, Interaction and BioAssay are occurrent,
while other data properties should also be incorporated
into the basic ontology so that their usage could be
maximized. For example, Utility classes and its subclas-
sess originally serve as helper classes for data integration
which are actually modeling artifacts. We did not intend
to further model individual major classes, as many of
them have their own domain ontology already (e.g., Dis-
ease Ontology), which can be incorporated into Chem2-
Bio2OWL accordingly. Since Chem2Bio2OWL initially
was fully based on BioPAX which is originally designed
for data integration and data exchange of the biological
p a t h w a yd a t aa n dh a sb e e nw i d e l yu s e d ,a l i g n m e n tw i t h
other basic ontologies needs a collaborative work with
BioPAX as well as OBO community.
In summary, we have demonstrated how semantic anno-
tation of systems chemical biology data allows scientifically
meaningful, complex queries to be succinctly specified in
SPARQL. We present an OWL ontology that was used to
annotate our Chem2Bio2RDF set, and is also available for
annotation of other integrative chemogenomics and sys-
tems chemical biology sets. This ontology was developed
through a set of specific scientific use cases, which we
believe has made it particularly scientifically relevant. We
are currently in the process of aligning this ontology to
other widely used ontologies including the Basic Formal
Ontology and a variety of biological sets.
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